Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) EBIT Margin (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed EBIT Margin for 5 consecutive years, with 82.2% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 1642.0% to 82.2% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 101.19% through Dec 2025, up 10285.0% year-over-year, with the annual reading at 101.19% for FY2025, 10284.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 82.2% at Rhythm Pharmaceuticals, up from 102.64% in the prior quarter.
  • The five-year high for EBIT Margin was 523.15% in Q4 2022, with the low at 98280.0% in Q1 2021.
  • Average EBIT Margin over 5 years is 6347.54%, with a median of 218.89% recorded in 2023.
  • The sharpest move saw EBIT Margin surged 9476258bps in 2022, then tumbled -69343bps in 2023.
  • Over 5 years, EBIT Margin stood at 2806.22% in 2021, then surged by 119bps to 523.15% in 2022, then tumbled by -133bps to 170.28% in 2023, then surged by 42bps to 98.63% in 2024, then increased by 17bps to 82.2% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 82.2%, 102.64%, and 93.39% for Q4 2025, Q3 2025, and Q2 2025 respectively.